Genetic architecture of heart failure with preserved versus reduced ejection fraction
Jacob Joseph, Chang Liu, Qin Hui, Krishna G. Aragam, Zeyuan Wang, Brian Charest, Jennifer E. Huffman, Jacob M. Keaton, Todd L. Edwards, Serkalem Demissie, Luc Djoussé, Juan P. Casas, J. Michael Gaziano, Kelly Cho, Peter W.F. Wilson, Lawrence S. Phillips, VA Million Veteran Program, Jennifer E. Huffman, Christopher J. O’Donnell, Yan V. Sun
Abstract
Pharmacologic clinical trials for heart failure with preserved ejection fraction have been largely unsuccessful as compared to those for heart failure with reduced ejection fraction. Whether differences in the genetic underpinnings of these major heart failure subtypes may provide insights into the disparate outcomes of clinical trials remains unknown. We utilize a large, uniformly phenotyped, single cohort of heart failure sub-classified into heart failure with reduced and with preserved ejection fractions based on current clinical definitions, to conduct detailed genetic analyses of the two heart failure sub-types. We find different genetic architectures and distinct genetic association profiles between heart failure with reduced and with preserved ejection fraction suggesting differences in underlying pathobiology. The modest genetic discovery for heart failure with preserved ejection fraction (one locus) compared to heart failure with reduced ejection fraction (13 loci) despite comparable sample sizes indicates that clinically defined heart failure with preserved ejection fraction likely represents the amalgamation of several, distinct pathobiological entities. Development of consensus sub-phenotyping of heart failure with preserved ejection fraction is paramount to better dissect the underlying genetic signals and contributors to this highly prevalent condition.